Amneal Pharmaceuticals Management

Management criteria checks 3/4

Amneal Pharmaceuticals' CEO is Chirag Patel, appointed in Jan 2005, has a tenure of 19.25 years. total yearly compensation is $2.37M, comprised of 31.6% salary and 68.4% bonuses, including company stock and options. directly owns 7.06% of the company’s shares, worth €119.26M. The average tenure of the management team and the board of directors is 4.8 years and 5.9 years respectively.

Key information

Chirag Patel

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage	31.6%
CEO tenure	19.3yrs
CEO ownership	7.1%
Management average tenure	4.8yrs
Board average tenure	5.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chirag Patel's remuneration changed compared to Amneal Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$2m	US$750k	-US$84m
Sep 30 2023	n/a	n/a	US$10m
Jun 30 2023	n/a	n/a	-US$2m
Mar 31 2023	n/a	n/a	-US$135m
Dec 31 2022	US$5m	US$750k	-US$130m
Sep 30 2022	n/a	n/a	-US$132m
Jun 30 2022	n/a	n/a	-US$134m
Mar 31 2022	n/a	n/a	US$2m
Dec 31 2021	US$5m	US$724k	US$11m
Sep 30 2021	n/a	n/a	US$14m
Jun 30 2021	n/a	n/a	US$9m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$2m	US$1	US$91m
Sep 30 2020	n/a	n/a	US$62m
Jun 30 2020	n/a	n/a	-US$194m
Mar 31 2020	n/a	n/a	-US$199m
Dec 31 2019	US$446k	US$44k	-US$362m
Sep 30 2019	n/a	n/a	-US$339m
Jun 30 2019	n/a	n/a	-US$67m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$325k	n/a	-US$21m

Compensation vs Market: Chirag's total compensation ($USD2.37M) is above average for companies of similar size in the German market ($USD1.62M).

Compensation vs Earnings: Chirag's compensation has been consistent with company performance over the past year.

CEO

Chirag Patel (56 yo)

19.3yrs

Tenure

US$2,370,385

Compensation

Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Chirag Patel	Co-Founder	19.3yrs	US$2.37m	7.06% $ 119.3m
Chintu Patel	Co-Founder	22.3yrs	US$2.37m	8.19% $ 138.3m
Anastasios Konidaris	Executive VP & CFO	4.1yrs	US$1.89m	0.17% $ 2.9m
Jason Daly	Senior VP	2.3yrs	US$1.35m	0.019% $ 313.9k
Nikita Shah	Executive VP & Chief Human Resources Officer	10.3yrs	US$1.53m	0.13% $ 2.1m
Andrew Boyer	Executive VP & Chief Commercial Officer of Generics	6.2yrs	US$1.94m	0.10% $ 1.7m
Anthony DiMeo	Head of Investor Relations	no data	no data	no data
Gregory Sgammato	Senior Vice President of Corporate Development	1.3yrs	no data	no data
Pranav Mehta	Senior VP of Strategic Sourcing & Supply Management	1.3yrs	no data	no data
Sanjay Jain	Chief Quality Officer	5.3yrs	no data	no data
Srinivas Kone	Senior VP & Chief Scientific Officer of Generics	4.3yrs	no data	no data
Stanley Fisher	Vice President & Head of Medical Affairs	no data	no data	no data

4.8yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 2DT's management team is considered experienced (4.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Chirag Patel	Co-Founder	19.3yrs	US$2.37m	7.06% $ 119.3m
Chintu Patel	Co-Founder	22.3yrs	US$2.37m	8.19% $ 138.3m
Paul Meister	Independent Chairman of the Board	4.7yrs	US$299.08k	0.20% $ 3.4m
J. Buchi	Independent Director	5.9yrs	US$302.20k	0.060% $ 1.0m
Ted Nark	Independent Director	5.9yrs	US$244.70k	0.073% $ 1.2m
Shlomo Yanai	Independent Director	4.3yrs	US$254.70k	0.055% $ 926.8k
Jeffrey George	Independent Director	4.3yrs	US$277.20k	0.063% $ 1.1m
Gautam Patel	Director	5.9yrs	US$217.20k	0.63% $ 10.6m
Deborah Autor	Independent Director	1.8yrs	US$267.04k	0.018% $ 300.9k
Emily Alva	Independent Director	5.9yrs	US$217.20k	0.057% $ 954.5k
John Kiely	Independent Director	4.3yrs	US$284.70k	0.058% $ 981.5k

5.9yrs

Average Tenure

56yo

Average Age

Experienced Board: 2DT's board of directors are considered experienced (5.9 years average tenure).

Amneal Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces Management Changes

Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty

Recent updates

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.86 loss in FY 2022)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Third quarter 2023 earnings released: EPS: US$0.063 (vs US$0.018 loss in 3Q 2022)

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Second quarter 2023 earnings released: EPS: US$0.078 (vs US$0.80 loss in 2Q 2022)

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Insufficient new directors

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$0.86 loss per share (vs US$0.071 profit in FY 2021)

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Insufficient new directors

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

Third quarter 2022 earnings released: US$0.018 loss per share (vs US$0.028 loss in 3Q 2021)

Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022

Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection

Amneal Pharmaceuticals, Inc. Announces Management Changes

Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS

Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty

Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.098 profit in 2Q 2021)

Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022

High number of new directors

Amneal Pharmaceuticals, Inc. Appoints Deborah M. Autor to Board of Directors

Amneal Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Amneal Pharmaceuticals, Inc. Announces Class Action Lawsuit Settlement Updates

Amneal Pharmaceuticals, Inc. Launches LYVISPAH for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)

First quarter 2022 earnings released: US$0.014 loss per share (vs US$0.045 profit in 1Q 2021)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)

Amneal Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022

Amneal Pharmaceuticals, Inc. Reports Asset Impairment Charges for the Three Months Ended December 31, 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Amneal Pharmaceuticals, Inc. Receives Approval of Releukotm

Amneal Pharmaceuticals, Inc. Expands Injectables Portfolio with 4 New Products

Amneal Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 02, 2022

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2021

Co-Founder recently bought €553k worth of stock

Co-Founder recently bought €553k worth of stock

Amneal Pharmaceuticals, Inc. Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations

Second quarter 2021 earnings released: EPS US$0.098 (vs US$0.081 loss in 2Q 2020)

Amneal Pharmaceuticals, Inc. Receives Approval for Generic TobraDex

Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab

Amneal Pharmaceuticals, Inc Announces That the Food and Drug Administration Recently Accepted Amneal’s 505(B)(2) New Drug Application for A Newly Licensed Dihydroergotamine

Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended March 31, 2021

First quarter 2021 earnings released: EPS US$0.045 (vs US$0.78 in 1Q 2020)

New 90-day high: €5.04

Investor sentiment improved over the past week